Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome (3-Star)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02738450
Recruitment Status : Completed
First Posted : April 14, 2016
Results First Posted : September 21, 2021
Last Update Posted : September 21, 2021
Sponsor:
Collaborators:
National Institute on Aging (NIA)
Alzheimer's Disease Cooperative Study (ADCS)
LuMind IDSC Foundation
Information provided by (Responsible Party):
AC Immune SA

Brief Summary:
The purpose of this study is to test in adults with Down Syndrome the safety, tolerability and immunogenicity of a vaccine, ACI-24.

Condition or disease Intervention/treatment Phase
Down Syndrome Biological: ACI-24 low dose Biological: ACI-24 high dose Biological: Placebo Phase 1

Detailed Description:

This is a prospective multi-center, placebo controlled, double-blind and randomized dose escalation study of 2 doses of ACI-24 versus Placebo over 24 months with a total of 21 visits.

All subjects will receive the study medication (ACI-24 or Placebo) 7 times via s.c. injection (12 months) and will be followed up for 12 months after the last dose with a final safety and efficacy assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome
Actual Study Start Date : March 2016
Actual Primary Completion Date : June 2020
Actual Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Down Syndrome

Arm Intervention/treatment
Active Comparator: ACI-24 low dose
Vaccine formulation will be administrated s.c. 7 times.
Biological: ACI-24 low dose
ACI-24 administered as a sterile suspension in PBS via s.c. injection.

Active Comparator: ACI-24 high dose
Vaccine formulation will be administrated s.c. 7 times.
Biological: ACI-24 high dose
ACI-24 administered as a sterile suspension in PBS via s.c. injection.

Placebo Comparator: Placebo
The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
Biological: Placebo
Placebo is a standard PBS sterile solution administrated via s.c. injection.
Other Name: PBS




Primary Outcome Measures :
  1. Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    The measure is expressed in Arbitrary Units per mL (AU/mL). AU/mL in a sample is obtained by back-calculation towards the standard curve.



Secondary Outcome Measures :
  1. Amyloid Beta 1-40 in Blood - Mean Absolute Value [ Time Frame: Values at baseline (week 0) and week 50 are reported ]
    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

  2. CANTAB - MOT Latency Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Cambridge Neuropsychological Test Automated Battery (CANTAB), Motor Screening Task (MOT) is a cognitive scale to be completed by the subject.

    Range score from 0 to ∞, lower score means a better outcome


  3. CANTAB - PAL First Attempt Memory Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Cambridge Neuropsychological Test Automated Battery (CANTAB), Paired Associate Learning (PAL) is a cognitive scale to be completed by the subject.

    Range score from 0 to 20, higher score means a better outcome


  4. Brief Praxis Test (BPT) - Total Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Brief Praxis Test (BPT) is a cognitive scale to be completed by the subject.

    Range score from 0 to 80, higher score means better outcome


  5. Vineland II - Communication Domain Standard Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.

    Range score from 0 to 113, higher score means a better outcome


  6. Vineland II - Daily Living Skill - Domain Standard Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.

    Range score from 0 to 114, higher score means a better outcome


  7. Vineland II - Socialisation - Domain Standard Score [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.

    Range score from 0 to 115, higher score means a better outcome


  8. NPI - Total Score [ Time Frame: Values at baseline (week 0) and week 50 are reported. ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Neuropsychiatric Inventory (NPI) is a behavioral questionnaire to be completed by the study partner of the subject.

    Range score from 0 to 144, higher score means a worse outcome


  9. Clinical Global Impression of Change (CGIC) - Change From Baseline at Week 50 [ Time Frame: Values at baseline (week 0) and week 50 are reported ]

    All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.

    Clinical Global Impression of Change (CGIC) is a global assessment to be completed by the investigator.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females with Down Syndrome aged ≥25 to ≤45 years, with a cytogenetic diagnosis being either Trisomy 21 or Complete Unbalanced Translocation of the Chromosome 21.
  • Subjects and their study partner/legal representative in the opinion of the investigator able to understand and to provide written informed consent.
  • Written informed consent obtained from subjects and their study partner/legal representative before any trial-related activities.
  • In the opinion of the investigator able to fully participate in the trial and sufficiently proficient in English to be capable of reliably completing study assessments.
  • Subjects have a study partner/legal representative who have direct contact with the subjects at least 10 hours per week and who can be asked questions about the subjects.

Exclusion Criteria:

  • Subjects weighing less than 40 kg.
  • IQ less than 40 (as assessed by Kaufman Brief Intelligence Test, Second Edition (KBIT-2).
  • In the investigators opinion, any clinically significant current psychiatric or neurologic illness, including a past illness with a risk of recurrence, other than Down syndrome.
  • Any medical condition likely to significantly hamper the evaluation of safety of the study drug.
  • DSM-IV criteria for drug or alcohol abuse or dependence currently met within the past five years.
  • History or presence of uncontrolled seizures. If history of seizures, they must be well controlled with no occurrence of seizures in the past 2 years prior to study screening. The use of anti-epileptic medications is permitted.
  • History of meningitis or meningoencephalitis.
  • History of malignant neoplasms within 3 years prior to study screening or where there is current evidence of recurrent or metastatic disease.
  • History of persistent cognitive deficits immediately following head trauma.
  • History of inflammatory neurology disorders.
  • History of autoimmune disease with potential for CNS involvement.
  • MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or evidence of a prior macrohemorrhage, or showing more than four cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite").
  • MRI examination cannot be done for any reason, including metal implants contraindicated for MRI studies and/or severe claustrophobia.
  • Significant hearing or visual impairment or other issues judged relevant by the investigator preventing to comply with the protocol and to perform the outcome measures.
  • Severe infections or a major surgical operation within 3 months prior to screening.
  • History of chronic or recurrent infections judged to be clinically significant by the investigator.
  • History or presence of immunological or inflammatory conditions which are judged to be clinically significant by the investigator.
  • Celiac disease not on a gluten free diet for at least 3 months prior to study screening.
  • Chronic benign skin pathologies, unless viewed as clinically insignificant in the investigator's opinion.
  • Any vaccine received within the past 2 months before baseline, except influenza vaccine which if indicated must be given at least 2 weeks prior to baseline.
  • Clinically significant arrhythmias or other abnormalities on ECG at screening. (Minor abnormalities documented as clinically insignificant by the investigator will be allowed.)
  • Clinically significant abnormal vital signs including sustained sitting blood pressure greater than 160/90 mmHg.
  • In the opinion of the site investigator, deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, that are judged to be clinically significant.
  • Subjects with treated hypothyroidism not on a stable dose of medication for at least 3 months prior to screening and having clinically significant abnormal serum T-4 and TSH at screening.
  • Subjects with diabetes mellitus with an HbA1c of ≥ 8.0%.
  • Subjects who have been receiving any experimental drug for Down Syndrome with a washout less than 30 days or less than five halflives of the drug, whichever is longer.
  • Female subjects being pregnant as confirmed by serum testing at screening or planning to be pregnant or lactating.
  • Female subjects not using a reliable method of contraception (unless abstaining).
  • Patient receiving any anticoagulant drug, or aspirin at doses greater than 100 mg daily in the 7 days prior to lumbar puncture (in order to avoid risk of bleeding during scheduled or unscheduled lumbar puncture)
  • Use of antidepressants other than SSRI/SNRIs at stable dose, antipsychotics (typical or atypical), GABA agonists (e.g. gabapentin), or stimulants (e.g. methylphenidate, modafinil). In exceptional cases, low doses of atypical antipsychotics (e.g. risperidone up to 0.5 mg/day or quetiapine up to 50 mg/day) or benzodiazepines are only allowed after review by the site principal investigator, in consultation with the project director and/or medical monitors.
  • Current use of immunosuppressant or immunomodulating drugs or their use within the past 6 months prior to study screening. Current use of steroids or their use within the past 3 months prior to study screening.
  • Use of Cholinesterase Inhibitor or use of Glutamatergic drugs (Topiramate, Memantine, Lamotrigine) if not on stable dose for at least 3 months prior to screening.
  • Subjects who have donated blood or blood products during the 30 days prior to screening who plan to donate blood while participating in the study or within four weeks after completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02738450


Locations
Layout table for location information
United States, Arizona
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics
Phoenix, Arizona, United States, 85013
United States, California
UCSD Adult Down Syndrome Program
La Jolla, California, United States, 92037-1712
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
AC Immune SA
National Institute on Aging (NIA)
Alzheimer's Disease Cooperative Study (ADCS)
LuMind IDSC Foundation
Investigators
Layout table for investigator information
Study Director: Michael S. Rafii, MD, PhD USC Keck School of Medicine of the University of Southern California, San Diego
  Study Documents (Full-Text)

Documents provided by AC Immune SA:
Study Protocol  [PDF] January 28, 2020
Statistical Analysis Plan  [PDF] September 18, 2020

Layout table for additonal information
Responsible Party: AC Immune SA
ClinicalTrials.gov Identifier: NCT02738450    
Other Study ID Numbers: ACI-24-1301
1R01AG047922-01 ( U.S. NIH Grant/Contract )
First Posted: April 14, 2016    Key Record Dates
Results First Posted: September 21, 2021
Last Update Posted: September 21, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Access to de-identified, individual and trial -level data (analysis datasets), and other information (e.g., protocols) will be provided.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Access Criteria: These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research and will be provided after review and approval of their research proposal, their Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). Data sharing shall be in accordance with ADCS' data sharing plan in its grant application and applicable NIH policy in effect at the time of the NIH award.
URL: https://www.adcs.org/
Keywords provided by AC Immune SA:
cognitive decline
Additional relevant MeSH terms:
Layout table for MeSH terms
Down Syndrome
Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn